A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
About
CellCentric is a clinical-stage biotechnology company focused on developing inobrodib, a novel oral p300/CBP inhibitor, for the treatment of multiple myeloma. The company recently completed an oversubscribed $220 million Series D financing round, which will be used to advance the development of inobrodib.
Tags
Total Employees
53
Current headcount
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does CellCentric do?
CellCentric is a clinical-stage biotechnology company focused on developing inobrodib, a novel oral p300/CBP inhibitor, for the treatment of multiple myeloma. The company recently completed an oversubscribed $220 million Series D financing round, which will be used to advance the development of inobrodib.
How much funding has CellCentric raised?
CellCentric has raised a total of $375M in funding. The most recent round on record is Series D.
Where is CellCentric headquartered?
CellCentric is headquartered in Cambridge, England, United Kingdom.
When was CellCentric founded?
CellCentric was founded in 2003.
What industry does CellCentric operate in?
CellCentric operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Medical, Therapeutics.
How many employees does CellCentric have?
CellCentric has approximately 53 people on record.
Similar Startups